Health Canada approves Baxter's 3-in-1 blood purification set for use in continuous renal replacement therapy and sepsis management protocols
Published: Jul 10, 2018
- New indication to help remove excessive levels of cytokines and endotoxins in patients needing blood purification makes oXiris the first 3-in-1 set available in Canada
- Elevated levels of specific cytokines and endotoxins are frequently seen in patients with sepsis, a serious medical condition and 12th leading cause of death in Canada1
MISSISSAUGA, ON, July 10, 2018 /CNW/ - Baxter Canada today announced Health Canada's approval of a new indication for the company's oXiris set, which can now be used to help remove excessive levels of cytokines, endotoxins and other inflammatory mediators from a patient's blood. oXiris is Canada's first blood purification set for simultaneous use in continuous renal replacement therapy (CRRT) and sepsis management protocols.
Previously, the oXiris set was only indicated for CRRT - a type of extracorporeal (outside of the body) blood purification (EBP) used with Baxter's Prismaflex system to manage patients with acute kidney injury (AKI). Often the result of illness, trauma or infection, AKI, is the sudden loss of kidney function that can create an accumulation of toxins and fluid in the blood that, if left untreated, may lead to death.
"Our mission to save and sustain lives is grounded in our determination to innovate across our portfolio in order to more effectively treat patients," said Stephen Thompson, President and General Manager, Baxter Canada. "The ICU is a particular focus, as patients are often battling very serious, complex, life-threatening conditions. Introducing products like oXiris, intended to advance care opportunities for the most critically ill, is a priority."
The use of EBP to remove cytokines and endotoxins from the blood represents a promising approach to treat conditions in patients with excessive levels of inflammatory mediators like cytokines and endotoxins, which are released by cells into the blood when the body becomes inflamed. One such condition is sepsis, which affects up to 40 percent of ICU patients worldwide 2,3,4,5,6,7,8 and currently has no proven effective therapies for treatment9. Research indicates that cytokines and endotoxins may contribute to the condition10,11,12.
Even with improvements in health care, the frequency of sepsis continues to increase. It is estimated that 1 in 18 deaths in Canada are related to sepsis, making it the 12th leading cause of death nationally. Although sepsis is not commonly cited as the primary cause of death, it is often a significant contributing factor. Approximately $325 million is spent annually in Canada to treat these complex patients1.
While EBP is being studied for its potential to help address sepsis, confirmation of an association is challenging due to the complexities of critically ill patients with AKI and/or sepsis, whom often require multiple therapeutic interventions13, making it difficult to assess individual treatment outcomes.
"It's extremely important for Baxter to bring our latest innovations to Canada," said Victoria Jurincic, Business Unit Head, Baxter Renal in Canada. "We are excited to launch this indication that will provide Canadian healthcare practitioners access to a promising new therapy option."
Baxter first showcased the indication in September 2017 when it received CE mark and regulatory approval for the label expansion in more than 30 countries in Europe and certain countries in the Middle East and Africa. Baxter currently plans to file for the expanded indication in additional countries. The oXiris set is not currently approved in the United States.
About Our Acute Therapies Portfolio
A leader in multi-organ support therapy options, Baxter has been at the forefront of advancing new technologies and revolutionizing treatment for critically ill patients around the world. Baxter's leading Prismaflex system offers clinicians the flexibility to meet patients' diverse needs and powers our portfolio of products to deliver a complete range of extracorporeal (outside the body) blood purification (EBP) therapies to help manage patients with AKI, acute respiratory distress syndrome, autoimmune diseases and/or sepsis. PrisMax, Baxter's next generation EBP system, is currently expected to launch commercially in select countries later in 2018.
About Baxter Canada
Every day, millions of patients and caregivers rely on Baxter's leading portfolio of critical care, nutrition, renal, hospital and surgical products. In Canada, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen for 80 years. With products, technologies and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. Baxter Canada and its nearly 1,000 employees are located primarily in Ontario at the Head Office, CIVA Admixing and Technical Services Centres in Mississauga, and in Alliston - where Baxter operates Canada's only large scale manufacturing plant producing life-sustaining intravenous and dialysis solutions. To learn more, visit www.baxter.ca and follow us on Twitter, LinkedIn and Facebook.
For safe and proper use of this device, refer to the full Instructions for use.
Baxter, oXiris, Prismaflex and PrisMax are registered trademarks of Baxter International Inc.
1 Canadian Sepsis Foundation. Understanding Sepsis. http://canadiansepsisfoundation.ca/understanding-sepsis/. Accessed on 15 Dec 2017.
2 Pavon A, Binquet C, Kara F, et al. Profile of the risk of death after septic shock in the present era: an epidemiologic study. Crit Care Med. 2013;41:2600-2609.
3 Blanco J, Muriel-Bombin A, Sagredo V, et al. Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study. Crit Care. 2008;12:R158.
4 Engel C, Brunkhorst FM, Bone HG, et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med. 2007;33:606-618.
5 Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med. 2004;30:589-596.
6 Karlsson S, Varpula M, Ruokonen E, et al. Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med. 2007;33:435-443.
7 Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA. 2014;311:1308-1316.
8 Sjoding MW, Prescott HC, Wunsch H, Iwashyna TJ, Cooke CR. Longitudinal changes in ICU admissions among elderly patients in the United States. Crit Care Med. 2016;44:1353-1360.
9 Rhodes A, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med 2017; 45:486-552.
10 Joannes-Boyau O, et al. Intensive Care Med 2013;39:1535--46.
11 Zhou F, et al. Crit Care Med 2013;41:2209--20.
12 Bernard GR, et al. N Engl J Med 2001;344;699--709.
13 Hébert PC, et al. Chest 2002;121:1290 - 300.
SOURCE Baxter Corporation